Cellectis SA

ALCLS

Company Profile

  • Business description

    Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

  • Contact

    8, rue de la Croix Jarry
    Paris75013
    FRA

    T: +33 181691600

    https://www.cellectis.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    222

Stocks News & Analysis

stocks

A collection of our best stock opportunities

Our latest articles about where we see opportunities in the market.
stocks

Morningstar analyst reacts to Macquarie Group’s earnings

Banking Analyst Nathan Zaia’s analysis of MQG’s results.
stocks

Undervalued ASX share showing progress in global efforts

More clarity on the path forward in the UK.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,966.703.200.04%
CAC 407,857.3656.480.72%
DAX 4024,217.37247.011.03%
Dow JONES (US)44,633.23204.33-0.46%
FTSE 1009,136.3254.880.60%
HKSE25,524.4537.68-0.15%
NASDAQ21,145.4833.11-0.16%
Nikkei 22540,674.55323.72-0.79%
NZX 50 Index12,936.4125.670.20%
S&P 5006,376.7213.05-0.20%
S&P/ASX 2008,704.606.900.08%
SSE Composite Index3,609.7111.770.33%

Market Movers